Todays milestone establishes Ozempic as an option for patients to help address two critical aspects of managing type 2 diabetes, blood sugar control and cardiovascular risk reduction, in those with known heart disease. Changes to Rybelsus Prescribing Information The Rybelsus (semaglutide) prescribing information has been updated in section 14 (clinical studies) to include an analysis from the primary endpoint of the PIONEER 6 CVOT showing the hazard ratio for time to first three-component MACE (HR 0.79 [95% CI: 0.57, 1.11]).[5] In June 2019, Novo Nordisk initiated the SOUL CVOT in 9,642 adults with type 2 diabetes and established cardiovascular disease to further evaluate the cardiovascular effect of Rybelsus
Collectively, these insights position GLP-1 and its analogs as versatile and promising agents in the broader context of metabolic disease management
What makes Parmesan Whisps a good low-carb snack
Diese Heterogenitt spiegelt die Zwischenposition dieses Peptids wider, das in den meisten Lndern weder ein zugelassenes Medikament noch eine streng kontrollierte Substanz ist
Schlee M, Hartmann G (2016) Discriminating self from non-self in nucleic acid sensing
Patients with a personal or family history of medullary thyroid cancer should not use any GLP-1 drug